Seth M. Birnbaum Joins the Board of Pharmaceutical Company Hallux Inc. | News

Bridgewater’s veteran partner brings to the company his capital-building experience as a pioneer in the subungal treatment for hard-to-cure onychomycosis.

LAGUNA HILLS, CA., May 18, 2022 /PRNewswire-PRWeb/ — Hallux Inc, a clinical-stage pharmaceutical company, today announced that following the initial closing of its $9.4 million Series A-2 Funding Round, Seasoned Partner of Bridgewater Associates Seth M. Birnbaum was appointed to its board of directors. Proceeds from the capital increase will be used to further fund the Company’s Phase 2 clinical program evaluating Hallux Subungual Gel (HSG) for the treatment of onychomycosis (nail fungus).

Hallux CEO Mark Taylor said: “On behalf of our entire board, we are delighted to have Seth join Hallux as a director. Our board members are both personally invested in Hallux and extremely experienced in clinical development, particularly onychomycosis Seth’s skill set and deep experience in capital formation and value creation are two critical disciplines needed by the company as we pursue our mission to provide patients around the world a very effective topical medication to cure this often difficult to treat infection.”

Seth M. Birnbaum, CFA is a 20-year veteran at Bridgewater Associates, where he is a partner and senior member of the investment team. His expertise includes economic market and investment analysis, risk management, and portfolio strategy and design. In 2019, Seth was named to the Institutional Investors Hedge Fund Rising Stars list. Seth graduated magna cum laude from Amherst College holder of a bachelor’s degree in economics, philosophy and political science, with honors. He is a board member of Open Doors.

About Hallux

Hallux Inc. is a clinical-stage pharmaceutical company focused on developing a new dosage form and route of administration for the treatment of onychomycosis (nail fungus). Hallux’s goal is to provide high efficacy and safety to patients with chronic onychomycosis worldwide. The Company’s experimental approach with its novel terbinafine HSG-based topical subungual drug candidate is to demonstrate safety and high efficacy through direct and selective delivery to the site of bedside infection. of the nail.

Media Contact

Mark TaylorCEO, Hallux Inc., 1 (949) 637-4656, [email protected]

TwitterLinkedIn, Facebook

SOURCE Hallux Inc.

Comments are closed.